Lori Rudolph-Owen, PhD
Lori is the Chief Operating Officer of Senda Biosciences, leading operations of the company’s R&D and platform functions and developing Senda’s clinical trials and regulatory capabilities. She brings over 22 years of leadership in pharmaceutical and biotechnology research and development, with particular expertise in strategic portfolio planning and development operations as well as driving effective cross-functional collaborations.
Prior to joining Senda, Lori was the Chief Development Officer at Goldfinch Bio where she was accountable for the strategic development and operational execution of the portfolio. Lori built the development organization from the ground up and drove GFB-887, a small molecule Trpc5 inhibitor, and GFB-024, a monoclonal CB-1 inverse agonist, from late-stage discovery through IND submission and into Ph2 proof of concept clinical development. While at Goldfinch, Lori was an integral member of the Executive Team responsible for the adjustment of the portfolio and optionality considerations for financing and strategic alternatives.
Prior to Goldfinch, Lori served as Vice President of Portfolio Management and Assessment at TESARO, Inc., where she built and led the portfolio development teams responsible for the U.S. and EU submissions and approvals of VARUBI® and ZEJULA®, as well as the filing of multiple investigational new drug (IND) applications. Before TESARO, Lori held positions of increasing leadership responsibility at Pfizer, AMAG Pharmaceuticals, MGI Pharma (now Eisai), Vertex and Millennium. She holds her Ph.D. in Cell Biology from Vanderbilt University’s School of Medicine and her B.A. in Biology from Carroll University. Lori also completed a postdoctoral research fellowship in the Biochemistry department at Vanderbilt University’s School of Medicine.